The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)

被引：3
|
作者：
Manns, M. [9 ]
Jeffers, L. [8 ]
Dalekos, G. [7 ]
Berg, T. [6 ]
Trepo, C. [5 ]
Roberts, S. [4 ]
Prieto, M. [3 ]
Rizzetto, M. [2 ]
Sorbel, J. [1 ]
Anderson, J. [1 ]
Mondou, E. [1 ]
Rousseau, F. [1 ]
机构：
[1] Gilead Sci Inc, Durham, NC USA
[2] Univ Turin, Dipartimento Gastroenterol, Turin, Italy
[3] Hosp La Fe, Serv Med Digestiva, E-46009 Valencia, Spain
[4] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[5] Hop Hotel Dieu, Serv Hepatogastroenterol, F-69288 Lyon, France
[6] Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany
[7] Univ Thessaly, Sch Med, Larisa, Greece
[8] Univ Miami, Sch Med, Miami, FL USA
[9] Hannover Med Sch, D-30623 Hannover, Germany
来源：
JOURNAL OF HEPATOLOGY | 2008年 / 48卷
关键词：
D O I：
10.1016/S0168-8278(08)60076-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
74
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [21] Low rate of delayed response in lamivudine experienced HIV/HBV co-infected patients treated with tenofovir disoproxil fumarate (TDF)
    Lada, O.
    Gervais, A.
    Branger, M.
    Peytavin, G.
    Colin, G.
    Fraqueiro, G.
    Males, S.
    Martinot-Peignoux, M.
    Matheron, S.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S259 - S259
  • [22] CLINICAL, VIROLOGICAL, SEROLOGICAL AND HISTOLOGICAL OUTCOMES IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 5 YEARS
    Buti, M.
    Fung, S.
    Gane, E.
    Afdhal, N.
    Flaherty, J.
    Martins, E.
    Bekele, N.
    Bornstein, J.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S197 - S198
  • [23] Clinical, virological, serological and histological outcomes in cirrhotic patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 5 years
    Sievert, William
    Strasser, Simone
    Gane, Ed
    George, Jacob
    Weilert, Frank
    Elsome, Amanda M.
    Flaherty, John F.
    Martins, Eduardo
    Bekele, Neby
    Bornstein, Jeffrey D.
    Buti, Maria
    Marcellin, Patrick
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 179 - 180
  • [24] Morphometric Assessment of Quantitative Collagen and Liver Fibrosis in Patients with Chronic Hepatitis B (CHB) Treated for up to Five Years with Tenofovir Disoproxil Fumarate (TDF)
    Goodman, Zachary D.
    Afdhal, Nezam H.
    Buti, Maria
    Gane, Edward J.
    Krastev, Zahary
    Schall, Raul E. Aguilar
    Kim, Sun Sook
    Alaparthi, Lakshmi
    Monge, Fanny
    Emmett, Caroline
    Bornstein, Jeffrey
    Subramanian, Mani
    McHutchison, John G.
    Dusheiko, Geoffrey M.
    Kaita, Kelly D.
    Manns, Michael P.
    Marcellin, Patrick
    HEPATOLOGY, 2013, 58 : 596A - 597A
  • [25] Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B
    Fung, Scott
    Kwan, Peter
    Fabri, Milotka
    Horban, Andrzej
    Pelemis, Mijomir
    Hann, Hie-Won
    Gurel, Selim
    Caruntu, Florin A.
    Flaherty, John F.
    Massetto, Benedetta
    Dinh, Phillip
    Corsa, Amoreena
    Subramanian, G. Mani
    McHutchison, John G.
    Husa, Petr
    Gane, Edward
    GASTROENTEROLOGY, 2014, 146 (04) : 980 - U521
  • [26] Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)
    Hie-Won Hann
    Hee Bok Chae
    Stephen R. Dunn
    Hepatology International, 2008, 2
  • [27] Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/TDF, and Entecavir in Patients with Decompensated Chronic Hepatitis B Liver Disease
    Liaw, Yun-Fan
    Sheen, I-Shyan
    Lee, Chuan-Mo
    Akarca, Ulus Salih
    Papatheodoridis, George V.
    Wong, Florence Suet-Hing
    Chang, Ting-Tsung
    Horban, Andrzej
    Wang, Chia
    Kwan, Peter
    Buti, Maria
    Prieto, Martin
    Berg, Thomas
    Kitrinos, Kathryn
    Peschell, Ken
    Mondou, Elsa
    Frederick, David
    Rousseau, Franck
    Schiff, Eugene R.
    HEPATOLOGY, 2011, 53 (01) : 62 - 72
  • [28] Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)
    Hann, Hie-Won
    Chae, Hee Bok
    Dunn, Stephen R.
    HEPATOLOGY INTERNATIONAL, 2008, 2 (02) : 244 - 249
  • [29] Randomized, Double-Blind, Placebo-Controlled Trial of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB)
    Chang, Mei-Hwei
    Park, Jae Hong
    Bezerra, Jorge A.
    Pacurar, Daniela
    Nijhawan, Sandeep
    Choe, Byung-Ho
    Kim, Kyung Mo
    Mehta, Rajiv M.
    Flaherty, John F.
    Wu, George
    Liu, Yang
    Reyes, Maribel
    Suri, Vithika
    Constantinescu, Alexandrina
    Choe, Yon-Ho
    Leung, Daniel H.
    HEPATOLOGY, 2018, 68 : 49A - 49A
  • [30] From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B
    Rodrigo, Minna
    Hartley, Christopher
    Wasuwanich, Paul
    Van, Trung
    Karnsakul, Wikrom
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (12) : 1099 - 1106
12345